Key statistics
On Thursday, ProMIS Neurosciences Inc (PMN:NAQ) closed at 0.955, 4.95% above its 52-week low of 0.91, set on Nov 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.99 |
---|---|
High | 0.99 |
Low | 0.95 |
Bid | 0.95 |
Offer | 0.99 |
Previous close | 0.9972 |
Average volume | 29.80k |
---|---|
Shares outstanding | 32.69m |
Free float | 23.68m |
P/E (TTM) | -- |
Market cap | 31.22m USD |
EPS (TTM) | -0.1931 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 20:13 GMT.
More ▼
- ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
- ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
- ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
- ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
- ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
- ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
- ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
- ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
- ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
More ▼